Diplomat Pharmacy (NYSE:DPLO) updated its FY19 earnings guidance on Tuesday. The company provided EPS guidance of ($4.91-4.81) for the period, compared to the Thomson Reuters consensus EPS estimate of ($2.66). The company issued revenue guidance of $4.9-5.1 billion, compared to the consensus revenue estimate of $4.87 billion.
Several brokerages recently weighed in on DPLO. Wells Fargo & Co boosted their price target on shares of Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a market perform rating in a research report on Tuesday, August 13th. Deutsche Bank assumed coverage on shares of Diplomat Pharmacy in a research report on Thursday, September 12th. They set a sell rating and a $4.00 price objective on the stock. ValuEngine upgraded shares of Diplomat Pharmacy from a buy rating to a strong-buy rating in a research report on Thursday, October 17th. Barclays set a $7.00 price objective on shares of Diplomat Pharmacy and gave the company a buy rating in a research report on Friday, August 9th. Finally, Zacks Investment Research upgraded shares of Diplomat Pharmacy from a sell rating to a hold rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Diplomat Pharmacy presently has an average rating of Hold and an average price target of $9.43.
DPLO stock traded down $3.64 during mid-day trading on Tuesday, reaching $2.56. 2,481,667 shares of the stock traded hands, compared to its average volume of 659,427. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99. Diplomat Pharmacy has a one year low of $4.17 and a one year high of $17.01. The stock has a market capitalization of $470.15 million, a PE ratio of 12.80 and a beta of 1.00. The business has a 50-day moving average price of $5.22 and a two-hundred day moving average price of $5.39.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01). The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The company’s revenue for the quarter was down 9.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) earnings per share. On average, equities analysts expect that Diplomat Pharmacy will post -0.81 earnings per share for the current fiscal year.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Article: Marijuana Stocks
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.